
# **Camil Castelo Branco**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7114293/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric, 2016, 19, 109-150.	1.1	676
2	Understanding weight gain at menopause. Climacteric, 2012, 15, 419-429.	1.1	430
3	The immune system and aging: a review. Gynecological Endocrinology, 2014, 30, 16-22.	0.7	321
4	Tolerability of different oral iron supplements: a systematic review. Current Medical Research and Opinion, 2013, 29, 291-303.	0.9	233
5	Quality of life after the menopause: a population study. Maturitas, 2000, 34, 17-23.	1.0	229
6	Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas, 2005, 52, 46-52.	1.0	223
7	Menopause and aging: Changes in the immune system—A review. Maturitas, 2010, 67, 316-320.	1.0	198
8	Skin collagen changes related to age and hormone replacement therapy. Maturitas, 1992, 15, 113-119.	1.0	176
9	Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas, 2000, 34, 161-168.	1.0	130
10	Relationship between skin collagen and bone changes during aging. Maturitas, 1994, 18, 199-206.	1.0	118
11	Side-Effects After IPL Photodepilation. Dermatologic Surgery, 2002, 28, 1131-1134.	0.4	116
12	Update on management of genitourinary syndrome of menopause: A practical guide. Maturitas, 2015, 82, 308-313.	1.0	111
13	Age at menopause in Latin America. Menopause, 2006, 13, 706-712.	0.8	105
14	Satisfaction and tolerance with office hysteroscopic tubal sterilization. Fertility and Sterility, 2008, 90, 1182-1186.	0.5	105
15	Prevalence of sexual dysfunction in a cohort of middle-aged women: influences of menopause and hormone replacement therapy. Journal of Obstetrics and Gynaecology, 2003, 23, 426-430.	0.4	104
16	Paradoxical Effect After IPL Photoepilation. Dermatologic Surgery, 2002, 28, 1013-1016.	0.4	101
17	Facial wrinkling in postmenopausal women. Effects of smoking status and hormone replacement therapy. Maturitas, 1998, 29, 75-86.	1.0	95
18	Periodontitis and osteoporosis: a systematic review. Climacteric, 2010, 13, 523-529.	1.1	92

#	Article	IF	CITATIONS
19	The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III): prevalence of the metabolic syndrome in postmenopausal Latin American women. Climacteric, 2007, 10, 164-170.	1.1	91
20	Complications of hysteroscopic Essure <sup>®</sup> sterilisation: report on 4306 procedures performed in a single centre. BJOC: an International Journal of Obstetrics and Gynaecology, 2012, 119, 795-799.	1.1	91
21	Current treatment options for postmenopausal vaginal atrophy. International Journal of Women's Health, 2018, Volume 10, 387-395.	1.1	81
22	Influence of psycho-social factors on climacteric symptoms. Maturitas, 2004, 48, 425-431.	1.0	79
23	Patients' and clinicians' attitudes after the Women's Health Initiative study. Menopause, 2004, 11, 57-61.	0.8	76
24	Stress symptoms and burnout in obstetric and gynaecology residents. BJOC: an International Journal of Obstetrics and Gynaecology, 2006, 114, 94-98.	1.1	70
25	The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas, 1996, 23, 307-312.	1.0	68
26	The relationships between mercury and selenium in plankton and fish from a tropical food web. Environmental Science and Pollution Research, 2009, 16, 10-24.	2.7	67
27	Therapeutic options for postmenopausal female sexual dysfunction. Climacteric, 2010, 13, 103-120.	1.1	65
28	Relationship between psychological complaints and vasomotor symptoms during climacteric. Maturitas, 2004, 49, 205-210.	1.0	64
29	Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. Maturitas, 2005, 50, 98-104.	1.0	53
30	Evidence-based assessment of the impact of the WHI on women's health. Climacteric, 2012, 15, 281-287.	1.1	53
31	Influence of high-intensity training and of dietetic and anthropometric factors on menstrual cycle disorders in ballet dancers. Gynecological Endocrinology, 2006, 22, 31-35.	0.7	52
32	Supplementation during pregnancy: beliefs and science. Gynecological Endocrinology, 2016, 32, 509-516.	0.7	52
33	Impairment of sexual activity in middle-aged women in Chile. Menopause, 2004, 11, 78-81.	0.8	51
34	Isolation and partial characterization of a lectin from Artocarpus incisa L. seeds. Phytochemistry, 1998, 47, 1183-1188.	1.4	50
35	Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Fertility and Sterility, 2007, 87, 702-705.	0.5	50
36	Impact of diabetes mellitus on the sexuality of Peruvian postmenopausal. Gynecological Endocrinology, 2008, 24, 470-474.	0.7	50

#	Article	IF	CITATIONS
37	Efficacy and safety of a phytoestrogen preparation derived from Glycine max (L.) Merr in climacteric symptomatology: A multicentric, open, prospective and non-randomized trial. Phytomedicine, 2002, 9, 85-92.	2.3	46
38	Comprehensive clinical management of hirsutism. Gynecological Endocrinology, 2010, 26, 484-493.	0.7	44
39	Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism. Gynecological Endocrinology, 2010, 26, 736-742.	0.7	44
40	Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone–stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels. Fertility and Sterility, 1999, 71, 261-267.	0.5	43
41	The effect of hormone replacement therapy on postmenopausal bone loss. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1992, 44, 131-136.	0.5	41
42	Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas, 2019, 124, 55-61.	1.0	41
43	Female contraception over 40. Human Reproduction Update, 2009, 15, 599-612.	5.2	40
44	Efficacy of Essure hysteroscopic sterilization – 5 years follow up of 1200 women. Gynecological Endocrinology, 2013, 29, 580-582.	0.7	40
45	Essure <sup>®</sup> and chronic pelvic pain: A population-based cohort. Journal of Obstetrics and Gynaecology, 2014, 34, 712-713.	0.4	40
46	The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric, 2015, 18, 233-240.	1.1	40
47	Changes in body mass index around menopause: a population study of Chilean woman. Menopause, 2001, 8, 239-244.	0.8	39
48	Bone mineral density in surgically postmenopausal women receiving hormonal replacement therapy as assessed by dual photon absorptiometry. Maturitas, 1993, 16, 133-137.	1.0	38
49	Sexual dysfunction and related risk factors in a cohort of middle-aged Ecuadorian women. Journal of Obstetrics and Gynaecology, 2006, 26, 682-686.	0.4	38
50	Early menopause: A hazard to a woman's health. Indian Journal of Medical Research, 2016, 143, 420.	0.4	37
51	Long-Term Compliance with Estrogen Replacement Therapy in Surgical Postmenopausal Women: Benefits to Bone and Analysis of Factors Associated with Discontinuation. Menopause, 1999, 6, 307-311.	0.8	36
52	Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study. Multiple Sclerosis Journal, 2016, 22, 564-568.	1.4	36
53	Bone mineral density in young, hypothalamic oligoamenorrheic women treated with oral contraceptives. Journal of reproductive medicine, The, 2001, 46, 875-9.	0.2	36
54	Effect of specific exercise training on bone mineral density in women with postmenopausal osteopenia or osteoporosis. Gynecological Endocrinology, 2009, 25, 616-620.	0.7	33

#	Article	IF	CITATIONS
55	Characteristics of post-menopausal women with genitourinary syndrome of menopause: Implications for vulvovaginal atrophy diagnosis and treatment selection. Maturitas, 2015, 81, 462-469.	1.0	33
56	Treatment persistence and compliance with a combination of calcium and vitamin D. Climacteric, 2010, 13, 578-584.	1.1	32
57	Turner's syndrome and other forms of congenital hypogonadism impair quality of life and sexual function. American Journal of Obstetrics and Gynecology, 2013, 208, 484.e1-484.e6.	0.7	32
58	Vulvar and vaginal atrophy as viewed by the Spanish REVIVE participants: symptoms, management and treatment perceptions. Climacteric, 2017, 20, 55-61.	1.1	32
59	Age, menopause and hormone replacement therapy influences on cardiovascular risk factors in a cohort of middle-aged Chilean women. Maturitas, 2003, 45, 205-212.	1.0	30
60	Management of osteoporosis in general practice: a cross-sectional survey of primary care practitioners in Spain. Osteoporosis International, 2004, 15, 252-257.	1.3	30
61	Menopausal transition in Movima women, a Bolivian native-American. Maturitas, 2005, 51, 380-385.	1.0	30
62	Isoflavones: effects on bone health. Climacteric, 2011, 14, 204-211.	1.1	30
63	Effects of oophorectomy and hormone replacement therapy on pituitary-gonadal function. Maturitas, 1993, 17, 101-111.	1.0	28
64	Secreting ovarian tumors may protect women from osteoporosis. Gynecologic Oncology, 2003, 88, 149-152.	0.6	27
65	Phytoestrogens and bone health at different reproductive stages. Gynecological Endocrinology, 2013, 29, 735-743.	0.7	27
66	Genitourinary Syndrome of Menopause: Current Treatment Options in Breast Cancer Survivors – Systematic Review. Maturitas, 2021, 143, 47-58.	1.0	27
67	Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: Effects on hair, bone, and hormone profile after 1-year use. Metabolism: Clinical and Experimental, 1997, 46, 437-440.	1.5	26
68	A scheme of combined oral contraceptives for women more than 40 years old. Menopause, 2001, 8, 286-289.	0.8	26
69	The effect of different hormone therapies on anti-müllerian hormone serum levels in anovulatory women of reproductive age. Gynecological Endocrinology, 2011, 27, 216-224.	0.7	26
70	Changes in bone turnover markers after calcium-enriched milk supplementation in healthy postmenopausal women: a randomized, double-blind, prospective clinical trial. Menopause, 2005, 12, 63-68.	0.8	25
71	Ovarian hyperstimulation, hyperprolactinaemia and LH gonadotroph adenoma. Reproductive BioMedicine Online, 2009, 19, 153-155.	1.1	25
72	Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy. Climacteric, 2016, 19, 60-65.	1.1	25

#	Article	IF	CITATIONS
73	Efficacy and safety of misoprostol, dinoprostone and Cook's balloon for labour induction in women with foetal growth restriction at term. Archives of Gynecology and Obstetrics, 2017, 296, 777-781.	0.8	25
74	Long-term safety and tolerability of flutamide for the treatment of hirsutism. Fertility and Sterility, 2009, 91, 1183-1188.	0.5	24
75	Effects of a long-acting gonadotropin-releasing hormone analog on the pituitary-ovarian-adrenal axis in women with severe hirsutism. Metabolism: Clinical and Experimental, 1996, 45, 24-27.	1.5	23
76	Spanish post-menopausal women's viewpoints on hormone therapy. Maturitas, 2007, 56, 420-428.	1.0	23
77	Quality of life and sexual function in women with polycystic ovary syndrome: a comprehensive review. Gynecological Endocrinology, 2020, 36, 96-103.	0.7	23
78	Vaginal laser therapy for genitourinary syndrome of menopause – systematic review. Maturitas, 2022, 156, 37-59.	1.0	23
79	Two-Year Prospective and Comparative Study on the Effects of Tibolone on Lipid Pattern, Behavior of Apolipoproteins Al and B. Menopause, 1999, 6, 92???97.	0.8	22
80	Use of hormone replacement therapy among Chilean women: a comparison between socioeconomic levels. Menopause, 2002, 9, 377-380.	0.8	22
81	Influences of hormone replacement therapy on postmenopausal women's health perceptions. Menopause, 2003, 10, 235-240.	0.8	22
82	Effect of androgens combined with hormone therapy on quality of life in post-menopausal women with sexual dysfunction. Gynecological Endocrinology, 2008, 24, 691-695.	0.7	22
83	Understanding how personality factors may influence quality of life. Menopause, 2008, 15, 914-918.	0.8	22
84	Luteal phase support with progesterone in intrauterine insemination: a prospective randomized study. Gynecological Endocrinology, 2014, 30, 197-201.	0.7	22
85	Sleep quality and related factors in postmenopausal women. Maturitas, 2019, 123, 73-77.	1.0	22
86	Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms – an update on the evidence. Climacteric, 2021, 24, 109-119.	1.1	22
87	Effects on bone <i>mass</i> of two oral contraceptives containing ethinyl-estradiol and cyproterone acetate or desogestrel: results of a 2-year follow-up. European Journal of Contraception and Reproductive Health Care, 1998, 3, 79-84.	0.6	20
88	Long-term postmenopausal hormone replacement therapy effects on bone mass: differences between surgical and spontaneous patients. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1999, 83, 207-211.	0.5	20
89	Transvaginal sonography of the endometrium in postmenopausal women: Monitoring the effect of hormone replacement therapy. Maturitas, 1994, 19, 59-65.	1.0	19
90	Definition and diagnosis of sexuality in the XXI century. Maturitas, 2008, 60, 50-58.	1.0	19

#	Article	IF	CITATIONS
91	Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens. A comparison. Journal of reproductive medicine, The, 1995, 40, 556-60.	0.2	19
92	Menstrual history as a determinant of current bone density in young hirsute women. Metabolism: Clinical and Experimental, 1996, 45, 515-518.	1.5	18
93	Female sexual dysfunction in postmenopausal women. Expert Opinion on Therapeutic Patents, 2007, 17, 639-647.	2.4	18
94	Impact of anthropometric parameters on quality of life during menopause. Fertility and Sterility, 2009, 92, 1947-1952.	0.5	18
95	Hepatotoxicity during low-dose flutamide treatment for hirsutism. Gynecological Endocrinology, 2009, 25, 419-422.	0.7	18
96	Risk of hypoactive sexual desire disorder and associated factors in a cohort of oophorectomized women. Climacteric, 2009, 12, 525-532.	1.1	18
97	Assessment of Quality of Life, Sexual Quality of Life, and Pain Symptoms in Deep Infiltrating Endometriosis Patients with or Without Associated Adenomyosis and the Influence of a Flexible Extended Combined Oral Contraceptive Regimen: Results of a Prospective, Observational Study. Iournal of Sexual Medicine. 2022. 19. 311-318.	0.3	18
98	Spanish consensus on sexual health in men and women over 50. Maturitas, 2014, 78, 138-145.	1.0	17
99	Outpatient hysteroscopic polypectomy: bipolar energy system (Versapoint®) versus diode laser – randomized clinical trial. Gynecological Endocrinology, 2016, 32, 196-200.	0.7	17
100	Gender differences in the prevalence of vitamin D deficiency in a southern Latin American country: a pilot study. Climacteric, 2020, 23, 410-416.	1.1	17
101	Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy. Menopause, 2003, 10, 534-537.	0.8	16
102	Vascular reactivity and atheromatous plaques in post-menopausal women on tibolone treatment. Maturitas, 2005, 50, 259-265.	1.0	16
103	The prescription of hormone replacement therapy in Spain: Differences between general practitioners and gynaecologists. Maturitas, 2006, 55, 308-316.	1.0	16
104	Women's perception of the efficacy of a soy extract with probiotic: The M3 study. Gynecological Endocrinology, 2008, 24, 178-183.	0.7	16
105	Effects of a 12-month multi-component exercise program on the body composition of postmenopausal women. Climacteric, 2014, 17, 155-163.	1.1	16
106	Transdermal estrogens do not appear to modify the extent of lesional areas of aortic atherosclerosis in oophorectomized rabbits on a cholesterol-rich diet. Atherosclerosis, 2000, 148, 303-308.	0.4	15
107	Continuation Rate of Combined Hormonal Contraception: A Prospective Multicenter Study. Journal of Women's Health, 2012, 21, 490-495.	1.5	15
108	Loss of smell but not taste in adult women with Turner's syndrome and other congenital hypogonadisms. Maturitas, 2012, 73, 244-250.	1.0	15

#	Article	IF	CITATIONS
109	Position of the Spanish Menopause Society regarding the management of menopausal symptoms in breast cancer patients. Maturitas, 2013, 75, 294-300.	1.0	15
110	Psychological Issues and Sexual Function in Women with Different Infertility Causes: Focus on Polycystic Ovary Syndrome. Reproductive Sciences, 2021, 28, 2830-2838.	1.1	15
111	Long-term Follow-up of Sexual Quality of Life after Laparoscopic Surgery in Patients with Deep Infiltrating Endometriosis. Journal of Minimally Invasive Gynecology, 2021, 28, 1912-1919.	0.3	15
112	Mycosis fungoides and pregnancy Oncology Reports, 2001, 8, 197-9.	1.2	15
113	Effects of transdermal estrogens on endothelial function in postmenopausal women with coronary disease. Climacteric, 2003, 6, 38-44.	1.1	14
114	Osteoporosis, fragility fracture, and periodontal disease. Menopause, 2013, 20, 79-84.	0.8	14
115	Quality of Life in Infertile Women with Polycystic Ovary Syndrome: a Comparative Study. Reproductive Sciences, 2021, 28, 1901-1909.	1.1	14
116	Management of Osteoporosis. Drugs and Aging, 1998, 12, 25-32.	1.3	13
117	Available medical choices for the management of menopause. Maturitas, 2005, 52, 61-70.	1.0	13
118	The dilemma of menopause and hormone replacement – a challenge for women and health-care providers: knowledge of menopause and hormone therapy in Spanish menopausal women. Climacteric, 2006, 9, 380-387.	1.1	13
119	Ovarian hyperstimulation syndrome. A new look at an old problem. Gynecological Endocrinology, 2019, 35, 651-656.	0.7	13
120	Solitary Vaginal Metastasis as a Presenting Form of Unsuspected Renal Adenocarcinoma. Gynecologic Oncology, 1994, 52, 260-263.	0.6	12
121	Effects on serum lipid and leptin levels of three different doses of norethisterone continuously combined with a fixed dose of 17l²-estradiol for nasal administration in postmenopausal women: a controlled, double-blind study. Fertility and Sterility, 2007, 88, 383-389.	0.5	12
122	Early prophylactic treatment in pregnant women during the 2009–2010 H1N1 pandemic: Obstetric and neonatal outcomes. Journal of Obstetrics and Gynaecology, 2013, 33, 128-134.	0.4	12
123	Local hormone therapy for genitourinary syndrome of menopause in breast cancer patients: is it safe?. Gynecological Endocrinology, 2017, 33, 418-420.	0.7	12
124	Management of menopause. Minerva Ginecologica, 2006, 58, 137-52.	0.8	12
125	Follicle-stimulating hormone does not directly regulate bone mass in human beings: evidence from nature. Fertility and Sterility, 2008, 90, 2211-2216.	0.5	11
126	Efficacy of ossein-hydroxyapatite complex compared with calcium carbonate to prevent bone loss. Menopause, 2009, 16, 984-991.	0.8	11

#	Article	IF	CITATIONS
127	Controversies over the use of GnRH agonists for reduction of chemotherapy-induced gonadotoxicity. Climacteric, 2016, 19, 522-525.	1.1	11
128	Sexuality and quality of life in congenital hypogonadisms. Gynecological Endocrinology, 2016, 32, 947-950.	0.7	11
129	Preventing postmenopausal bone loss with ossein-hydroxyapatite compounds. Results of a two-year, prospective trial. Journal of reproductive medicine, The, 1999, 44, 601-5.	0.2	11
130	Effects of oophorectomy and hormone replacement therapy on plasma lipids. Maturitas, 1993, 17, 113-122.	1.0	10
131	Do Patients Lie? An Open Interview vs. a Blind Questionnaire on Sexuality. Journal of Sexual Medicine, 2010, 7, 873-880.	0.3	10
132	Management of Turner syndrome in adult life and beyond. Maturitas, 2014, 79, 471-475.	1.0	10
133	What can we do to reduce the associated costs in induction of labour of intrauterine growth restriction foetuses at term? A cost-analysis study. Archives of Gynecology and Obstetrics, 2017, 296, 483-488.	0.8	10
134	Physiology of intraâ€abdominal volume during pregnancy. Journal of Obstetrics and Gynaecology, 2021, 41, 1016-1022.	0.4	10
135	Gynaecological short communication: Compliance with hormone replacement therapy at the menopause. Journal of Obstetrics and Gynaecology, 1995, 15, 204-205.	0.4	9
136	Hyperandrogenism in post-menopausal women: a diagnosis challenge. Gynecological Endocrinology, 2014, 30, 23-25.	0.7	9
137	Hearing loss in adult women with Turner's syndrome and other congenital hypogonadisms. Gynecological Endocrinology, 2014, 30, 111-116.	0.7	9
138	Impact Of Vulvovaginal Atrophy Of Menopause In Spanish Women: Prevalence And Symptoms According To The EVES Study. Sexual Medicine, 2019, 7, 207-216.	0.9	9
139	Changes in bone mass and body composition after bariatric surgery. Gynecological Endocrinology, 2020, 36, 578-581.	0.7	9
140	Comparison of a New Reusable Gynecologic Laparoscopic Electric Morcellator with a Disposable Morcellator: a Preliminary Trial. Journal of Minimally Invasive Gynecology, 2009, 16, 595-598.	0.3	8
141	Contraception knowledge and sexual behaviour in secondary school students. Gynecological Endocrinology, 2010, 26, 479-483.	0.7	8
142	Effects of body composition and menopause characteristics on maximal oxygen uptake of postmenopausal women. Menopause, 2011, 18, 1191-1197.	0.8	8
143	Alcohol and drug abuse and risky sexual behaviours in young adult women. Gynecological Endocrinology, 2014, 30, 581-586.	0.7	8
144	Efficacy and safety of ossein-hydroxyapatite complex versus calcium carbonate to prevent bone loss. Climacteric, 2020, 23, 252-258.	1.1	8

#	Article	IF	CITATIONS
145	Genitourinary syndrome of menopause assessment tools. Journal of Mid-Life Health, 2021, 12, 99.	0.4	8
146	Primary adenocarcinoma of the endometrium associated with genital tuberculosis. A case report. Journal of reproductive medicine, The, 1995, 40, 673-5.	0.2	8
147	Effects of estradiol, cyproterone acetate, tibolone and raloxifene on uterus and aorta atherosclerosis in oophorectomized cholesterol-fed rabbits. Maturitas, 2003, 45, 59-66.	1.0	7
148	Alendronate daily, weekly in conventional tablets and weekly in enteric tablets: preliminary study on the effects in bone turnover markers and incidence of side effects. Journal of Obstetrics and Gynaecology, 2003, 23, 278-281.	0.4	7
149	Raloxifene inhibits cholesterol aortic content but not atherosclerotic plaque size in oophorectomised cholesterol-fed rabbits. Journal of Obstetrics and Gynaecology, 2004, 24, 47-51.	0.4	7
150	Treatment of atrophic vaginitis. Therapy: Open Access in Clinical Medicine, 2007, 4, 349-353.	0.2	7
151	Management of Turner's syndrome in adult life: case-series and systematic review. Gynecological Endocrinology, 2012, 28, 726-732.	0.7	7
152	Panoramic radiomorphometry and vertebral fractures in Spanish postmenopausal women. Maturitas, 2013, 76, 364-369.	1.0	7
153	Use of ossein–hydroxyapatite complex in the prevention of bone loss: a review. Climacteric, 2015, 18, 29-37.	1.1	7
154	Essure a novel option for the treatment of hydrosalpinx: a case series and literature review. Gynecological Endocrinology, 2016, 32, 166-170.	0.7	7
155	Use of hormone therapy for menopausal symptoms and quality of life in breast cancer survivors. Safe and ethical?. Gynecological Endocrinology, 2017, 33, 10-15.	0.7	7
156	Hidradenoma papilliferum of the vulva in a postpartum woman: A case report. Journal of Obstetrics and Gynaecology, 2017, 37, 683-684.	0.4	7
157	High persistence in Spanish transgender minors: 18 years of experience of the Gender Identity Unit of Catalonia. Revista De PsiquiatrÃa Y Salud Mental, 2024, 17, 35-40.	1.0	7
158	Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins AI and B. Menopause, 1999, 6, 92-7.	0.8	7
159	Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study. Climacteric, 2022, 25, 476-482.	1.1	7
160	Use of gonadotropin-releasing hormone analog with tibolone to prevent cyclic attacks of acute intermittent porphyria. Metabolism: Clinical and Experimental, 2001, 50, 995-996.	1.5	6
161	Effect of continuous and sequential oral estrogen–progestogen replacement regimens on postmenopausal bone loss: a 2-year prospective study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2001, 99, 261-265.	0.5	6
162	Efficacy and Safety of Ibuprofen Arginine in the Treatment of Primary Dysmenorrhoea. Clinical Drug Investigation, 2004, 24, 385-393.	1.1	6

#	Article	IF	CITATIONS
163	Hormone therapy for the management of the menopause in Ecuador: Perception, use and knowledge among middle-aged women. Gynecological Endocrinology, 2008, 24, 580-585.	0.7	6
164	The role of intranasal estradiol spray in the management of moderate to severe vasomotor symptoms in menopausal women. Gynecological Endocrinology, 2010, 26, 23-29.	0.7	6
165	Optimizing soy isoflavones effect in postmenopausal women: the impact of timing on climacteric symptoms. Gynecological Endocrinology, 2011, 27, 696-700.	0.7	6
166	Normal and gestational diabetic pregnancies. Lipids, lipoproteins and apolipoproteins. Journal of reproductive medicine, The, 1998, 43, 144-8.	0.2	6
167	Plasma lipids, lipoproteins and apolipoproteins in hirsute women. Acta Obstetricia Et Gynecologica Scandinavica, 1996, 75, 261-265.	1.3	5
168	Compounds for the treatment of atropic vaginitis. Expert Opinion on Therapeutic Patents, 2008, 18, 1385-1394.	2.4	5
169	Unintended pregnancy after long-term Essure microinserts placement. Fertility and Sterility, 2010, 94, 2793-2795.	0.5	5
170	Vaginal misoprostol and cervical ripening balloon for induction of labor in lateâ€ŧerm pregnancies. Journal of Obstetrics and Gynaecology Research, 2017, 43, 87-91.	0.6	5
171	Ossein-hydroxyapatite compounds for preventing postmenopausal bone loss. Coadjuvant use with hormone replacement therapy. Journal of reproductive medicine, The, 1999, 44, 241-6.	0.2	5
172	Sexual Function in Breast Cancer Patients: A Review of the Literature. Clinical and Experimental Obstetrics and Gynecology, 2022, 49, 134.	0.1	5
173	Hormone replacement therapy and changes on pituitary function. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1992, 43, 59-63.	0.5	4
174	Is MRI helpful in evaluating the response of cervical cancer to neoadjuvant chemotherapy?. Acta Obstetricia Et Gynecologica Scandinavica, 1995, 74, 467-471.	1.3	4
175	A simplified method to quantitate atherosclerosis in the rabbit aorta. Maturitas, 2001, 39, 265-271.	1.0	4
176	Effect of a compound containing isoflavones, primrose oil and vitamin E in two different doses on climacteric symptoms. Journal of Obstetrics and Gynaecology, 2006, 26, 344-347.	0.4	4
177	Educational and organizational interventions used to improve the knowledge of metabolic syndrome among postmenopausal women. Fertility and Sterility, 2008, 90, 444-446.	0.5	4
178	Pregnancy following radical vulvectomy for carcinoma of the vulva: a case report and literature review. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 158, 113-114.	0.5	4
179	Further data favouring hormonal dependency of cerebral meningiomas: evidence from a patient treated with cabergoline. Gynecological Endocrinology, 2011, 27, 134-137.	0.7	4
180	Comparative cytogenetic analysis in two tissues with different lineage in Turner's syndrome patients: correlation with phenotype. Gynecological Endocrinology, 2014, 30, 282-286.	0.7	4

#	Article	IF	CITATIONS
181	iContraception®: a software tool to assist professionals in choosing contraceptive methods according to WHO medical eligibility criteria. Journal of Family Planning and Reproductive Health Care, 2015, 41, 142-145.	0.9	4
182	A trial of oral nifedipine and oral labetalol in preeclampsia hypertensive emergency treatment. Journal of Obstetrics and Gynaecology, 2017, 37, 864-866.	0.4	4
183	Anterior abdominal wall parasitic leiomyoma: case report. Gynecological Endocrinology, 2018, 34, 103-106.	0.7	4
184	Postmenopausal hormone replacement therapy with low-dose medroxyprogesterone acetate. Endometrium, plasma lipids, lipoproteins and apolipoproteins. Journal of reproductive medicine, The, 1995, 40, 305-11.	0.2	4
185	Long-term effect of hormone therapy on bone in early menopause: vertebral fractures after 20 years. Climacteric, 2014, 17, 336-341.	1.1	3
186	Comparison of the effects of calcium carbonate and ossein–hydroxyapatite complex on back and knee pain and quality of life in osteopenic perimenopausal women. Maturitas, 2015, 81, 76-82.	1.0	3
187	Long-term satisfaction and tolerability with low-dose flutamide: a 20-year surveillance study on 120 hyperandrogenic women. Gynecological Endocrinology, 2016, 32, 723-727.	0.7	3
188	Cardiovascular risk in climacteric women: focus on diet. Climacteric, 2016, 19, 215-221.	1.1	3
189	Alternative strategies for the management of ovarian hyperstimulation syndrome, the role of intra-abdominal hypertension control. Gynecological Endocrinology, 2020, 36, 197-203.	0.7	3
190	Are we assessing genitourinary syndrome of menopause properly?. Climacteric, 2021, 24, 529-530.	1.1	3
191	Letters to the Editor. Menopause, 2000, 7, 417.	0.8	3
192	Weight gain in menopause: systematic review of adverse events in women treated with black cohosh. Climacteric, 2022, 25, 220-227.	1.1	3
193	Effects of transdermal estrogens on endothelial function in postmenopausal women with coronary disease. Climacteric, 2003, 6, 38-44.	1.1	3
194	Black cohosh efficacy and safety for menopausal symptoms. The Spanish Menopause Society statement. Gynecological Endocrinology, 2022, 38, 379-384.	0.7	3
195	Vaginal Hysterectomy with the Autosuture Stapler. Journal of Gynecologic Surgery, 1994, 10, 21-25.	0.0	2
196	Cyproterone acetate could counteract the benefits of estradiol valerate in oophorectomized cholesterol-fed rabbits. Menopause, 2002, 9, 282-287.	0.8	2
197	Unintended pregnancy after gonadal failure chemoprevention with gonadotropin-releasing hormone agonist in women with hematologic malignancies. Fertility and Sterility, 2009, 92, 1260-1263.	0.5	2
198	Posicionamiento de la Asociación Española para el Estudio de la Menopausia sobre el uso clÃnico de la CimicÃfuga racemosa en el climaterio. Progresos En Obstetricia Y Ginecologia, 2009, 52, 712-721.	0.0	2

#	Article	IF	CITATIONS
199	CLINICAL ASPECTS AND RELATIONSHIPS BETWEEN WEIGHT GAIN, OBESITY AND MENOPAUSE. Maturitas, 2009, 63, S19.	1.0	2
200	Recomendaciones de la Sociedad Española de GinecologÃa y Obstetricia sobre la prevención y el tratamiento de la atrofia vaginal. Progresos En Obstetricia Y Ginecologia, 2012, 55, 408-415.	0.0	2
201	Diagnosis and Surgical Treatment of Uterine Isthmus Atresia: A Case Report and Review of the Literature. Journal of Minimally Invasive Gynecology, 2021, 28, 137-141.	0.3	2
202	Assessing the Usefulness of Severity Markers in Women with Ovarian Hyperstimulation Syndrome. Reproductive Sciences, 2021, 28, 1041-1048.	1.1	2
203	Psychopathological symptoms in Spanish subjects with gender dysphoria. A cross-sectional study. Gynecological Endocrinology, 2021, 37, 534-540.	0.7	2
204	Management of symptomatic uterine fibroids after ulipristal acetate suspension and identification of high risk patients for surgery at 6-months of follow-up. Gynecological Endocrinology, 2021, 37, 831-835.	0.7	2
205	Effects of transdermal estrogens on endothelial function in postmenopausal women with coronary disease. Climacteric, 2003, 6, 38-44.	1.1	2
206	Effects of progestogen on lipids, lipoproteins and apolipoproteins during transdermal estrogen replacement therapy with and without medroxyprogesterone acetate. Journal of reproductive medicine, The, 1996, 41, 833-8.	0.2	2
207	Intravaginal misoprostol versus uterine curettage for missed abortion: A costâ€effectiveness analysis. Journal of Obstetrics and Gynaecology Research, 2022, , .	0.6	2
208	Antagonism of oestrogen-induced prolactin release by medroxyprogesterone acetate. Maturitas, 1994, 20, 145-150.	1.0	1
209	Umbilical cord torsion; a rare cause of intra-uterine fetal death. Journal of Obstetrics and Gynaecology, 1994, 14, 324-325.	0.4	1
210	P-95 Menopause, 1997, 4, 286.	0.8	1
211	Posterior Vaginal Wall Repair with Synthetic Absorbable Mesh: A New Technique for an Old Procedure. Journal of Gynecologic Surgery, 1998, 14, 111-117.	0.0	1
212	Do women using hormone replacement treatment have less pre-existing cardiovascular risk. Maturitas, 2001, 38, 315-319.	1.0	1
213	Evaluación clÃnica y terapéutica del hirsutismo. Piel, 2002, 17, 428-436.	0.0	1
214	Calcium-fortified milk early in the postmenopausal period delays bone loss in the spine. Evidence-Based Healthcare and Public Health, 2002, 6, 12-13.	0.0	1
215	Operación de Vecchietti por laparoscopia para la creación de una neovagina en el sÃndrome de Mayer-Rokitansky-Kuster-Hauser. Evaluación anatomicofuncional. Progresos En Obstetricia Y Ginecologia, 2004, 47, 367-372.	0.0	1
216	Statins and cancer: Harmful or helpful?. Maturitas, 2011, 68, 198.	1.0	1

#	Article	IF	CITATIONS
217	Climacteric. Climacteric, 2012, 15, 500-510.	1.1	1
218	Revisiting lactic acidosis in an HIV-1 infected pregnant woman on antiretroviral therapy. Journal of Obstetrics and Gynaecology, 2013, 33, 310-311.	0.4	1
219	Clinical efficacy of estradiol transdermal system in the treatment of hot flashes in postmenopausal women. Research and Reports in Transdermal Drug Delivery, 0, , 1.	0.0	1
220	The results of different labour induction approaches: A Cross sectional study. Obstetrics & Gynecology International Journal, 2021, 12, 108-111.	0.0	1
221	Different Lifestyles in Young Women From Urban and Rural Areas May Explain Different Cardiovascular Risk. Vascular Disease Prevention, 2006, 3, 79-82.	0.2	1
222	Teenage Pregnancy in Argentina: A Reality. , 2014, , 171-189.		1
223	Pre-induction cervical ripening with different initial doses of intravaginal misoprostol: time to delivery and peri-natal outcomes. Journal of Obstetrics and Gynaecology, 2022, 42, 1112-1116.	0.4	1
224	Calcium-collagen chelate supplementation reduces bone loss in osteopenic postmenopausal women. Climacteric, 2015, 18, 105-6.	1.1	1
225	Pitfalls in mammography screening policy: Breast cancer in a 26-year-old patient. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1993, 48, 141-144.	0.5	Ο
226	P022 Evolution of the effect of hormonal replacement therapy in bone mineral density in postmenopausal women. Maturitas, 1996, 27, 122.	1.0	0
227	P023 Bone mineral density in spontaneous and surgically postmenopausal women receiving hormonal replacement therapy. Maturitas, 1996, 27, 123.	1.0	Ο
228	P190 Long term hormonal replacement therapy (5 years) and lipid profile changes. Maturitas, 1996, 27, 176.	1.0	0
229	P-96 Menopause, 1997, 4, 287.	0.8	Ο
230	Sistema cardiovascular y menopausia. Semergen, 2000, 26, 133-135.	0.2	0
231	Piel y menopausia: influencia de los estrógenos y del tratamiento hormonal sustitutivo en el envejecimiento cutáneo. Piel, 2003, 18, 153-159.	0.0	Ο
232	Terapia hormonal sustitutiva a bajas dosis. Clinica E Investigacion En Ginecologia Y Obstetricia, 2004, 31, 161-168.	0.1	0
233	Hiperandrogenismo ovárico. Valoración clÃnica y terapéutica. Clinica E Investigacion En Ginecologia Y Obstetricia, 2005, 32, 244-256.	0.1	0
234	Pain in fibromyalgia patients. Therapy: Open Access in Clinical Medicine, 2007, 4, 193-200.	0.2	0

#	Article	IF	CITATIONS
235	QUALITY OF LIFE, CLINICAL ASPECTS AND RELATIONSHIPS BETWEEN OBESITY AND MENOPAUSE. Maturitas, 2009, 63, S56.	1.0	Ο
236	Long-Term Safety and Tolerability of Flutamide for the Treatment of Hirsutism. Obstetrical and Gynecological Survey, 2009, 64, 598-599.	0.2	0
237	Quality of Life after Laparoscopic Excision of Rectovaginal Endometriosis: Results of a Pilot Study. Journal of Minimally Invasive Gynecology, 2010, 17, S135.	0.3	0
238	Analysis of the Risk Factors of Complication and Conversion in Laparoscopic Myomectomies. Journal of Minimally Invasive Gynecology, 2010, 17, S145.	0.3	0
239	Quality of Sex Life after Laparoscopic Treatment of Rectovaginal Endometriosis: Results of a Pilot Study. Journal of Minimally Invasive Gynecology, 2010, 17, S135.	0.3	0
240	Climacteric Commentaries. Climacteric, 2011, 14, 689-695.	1.1	0
241	Climacteric Commentaries. Climacteric, 2012, 15, 95-102.	1.1	0
242	Recomendaciones sobre ranelato de estroncio en el tratamiento de la osteoporosis. Progresos En Obstetricia Y Ginecologia, 2012, 55, 38-49.	0.0	0
243	M234 INCIDENCE OF ADVERSE EFFECTS IN FOUR ORAL IRON FORMULATIONS: A SYSTEMATIC REVIEW. International Journal of Gynecology and Obstetrics, 2012, 119, S607.	1.0	0
244	Fracturas vertebrales tras tratamiento hormonal en la menopausia: 20 años de seguimiento. Progresos En Obstetricia Y Ginecologia, 2013, 56, 462-466.	0.0	0
245	Senshio $\hat{A}^{\otimes}$ , a new oral treatment for VVA. Maturitas, 2015, 82, 321-322.	1.0	0
246	Complementary and Alternative Therapies for Menopausal Vasomotor Symptoms. , 2017, , 261-272.		0
247	Management of Transsexuality in anÂOutpatient Gynecologic Area. ISGE Series, 2019, , 155-166.	0.2	0
248	Urinary incontinence in climacteric afrodescendant women from the Colombian Caribbean. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2019, 8, 3817.	0.0	0
249	Use of Radioactive Seed Localization to Guide Removal of a Nonpalpable Endometriotic Lesion: A Case Report. Journal of Minimally Invasive Gynecology, 2020, 27, 551-554.	0.3	0
250	Prasterona en el tratamiento del sÃndrome genitourinario de la menopausia. Clinica E Investigacion En Ginecologia Y Obstetricia, 2021, 48, 67.	0.1	0
251	Effects of anthropometric parameters on bone mineral density in women: from perimenopause to old age. Gynecological Endocrinology, 2021, 37, 902-905.	0.7	0
252	Current lifestyle and exclusive breastfeeding: an impossible balance?. Journal of Obstetrics and Gynaecology, 2021, , 1-4.	0.4	0

#	Article	IF	CITATIONS
253	Dr. Castelo-Branco replies:. Menopause, 2000, 7, 417-418.	0.8	Ο
254	Effect of Androgenic and Antiandrogenic Acting Compounds in Macrophage Accumulation and Cell Replication in the Aorta of Oophorectomized Hypercholesterolemic Rabbits. Vascular Disease Prevention, 2008, 3, 369-374.	0.2	0
255	Cardiovascular Risk During the Menopause. Vascular Disease Prevention, 2009, 6, 103-108.	0.2	0
256	Prevalence and risk factors for sexual dysfunction in gynecologic tumors survivors Journal of Clinical Oncology, 2010, 28, e19622-e19622.	0.8	0
257	Adolescent Pregnancy in Portugal. , 2014, , 523-534.		0
258	SintomatologÃa vasomotora y terapias alternativas a la terapia hormonal de reemplazo. Revista Colombiana De Obstetricia Y Ginecologia, 1999, 50, 107-111.	0.2	0
259	Induction of Labour: Eternal Controversy. International Journal of Pregnancy & Child Birth, 2017, 3, .	0.0	0
260	Turner Syndrome: Primary Amenorrhea from Adolescence to Aging. , 2019, , 19-32.		0
261	Tibolone inhibits aortic atherosclerotic lesionformation in oophorectomized cholesterol-fed rabbits. Experimental and Clinical Cardiology, 2003, 8, 21-5.	1.3	0
262	Two Sisters with Kallmann Syndrome, Gonadal Dysgenesis, and Multiple Neuromuscular and Endocrine Disorders: Report of Two Cases with Description of an Unusual Association. Reproductive Sciences, 2022, , 1.	1.1	0
263	Are anthropometric data a tool for determining the severity of OHSS? Yes, it could be!. BMC Women's Health 2022, 22, 155	0.8	0